Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer [Phase 2]
A Phase II trial investigating Almonertinib in combination with Lastet for EGFR-positive non-small cell lung cancer; the study is not yet re…
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
Cadonilimab is being studied in Phase 1/2 trials for advanced non-small cell lung cancer. The study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating whether dexamethasone-induced senescence can re-sensitize non-small cell lung cancer to PD-1 inhibitors;…
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC [Phase 3]
Phase 3 clinical trial update comparing ASK120067 to Gefitinib as first-line treatment for EGFR-mutant locally advanced or metastatic non-sm…
-
FDA approval · 2024-06-14FDA Approved: PEMETREXED — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic pemetrexed disodium, enabling manufacturing and marketing of this ge…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
Phase 1/2 trial evaluating selinexor with docetaxel in non-small cell lung cancer was terminated, with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors [Phase 1]
Phase 1 trial update for ADCT-301 (camidanlumab tesirine) in selected advanced solid tumors; the study has been terminated and results have …
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC [Phase 1, Phase 2]
An early-stage trial is evaluating trametinib plus anlotinib with tislelizumab for KRAS-mutant non-small cell lung cancer; the Phase 1/2 stu…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations [Phase 1, Phase 2]
A study of TPX-0046, a RET/SRC inhibitor, in adults with advanced solid tumors including non-small cell lung cancer and medullary thyroid ca…
-
CLINICAL_TRIALS research · 2024-06-13Clinical Trial Update: A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]
A clinical trial update for SHR-A1811 in advanced non-small cell lung cancer (Phase 1/Phase 2). The study is sponsored by Jiangsu HengRui Me…
-
FDA approval · 2024-06-12FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly and Company.
-
FDA label_change · 2024-06-12FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly, indicating an update to the drug’s labeling. The action …
-
CLINICAL_TRIALS withdrawal · 2024-06-12Clinical Trial Update: To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer [Phase 3]
Clinical trial NCT02974426, a Phase 3 study evaluating the timing of postoperative radiotherapy in stage IIIA (N2) non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Trop2 CAR-NK therapy for relapsed/refractory non-small cell lung cancer, currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation [Phase 1]
Phase 1 trial assessing Capmatinib plus Trametinib for metastatic non-small cell lung cancer with MET exon 14 skipping mutation; the study s…
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer
This clinical trial update discusses implementing TNM-immunoscore as a prognostic tool in patients with resected non-small cell lung cancer.…
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. [Phase 2]
Phase 2 clinical trial update of Gumarontinib in combination with a third EGFR-TKI for non-small cell lung cancer; the study is not yet recr…
-
CLINICAL_TRIALS research · 2024-06-10Clinical Trial Update: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer [Phase 1]
This Phase 1 study is evaluating the combination of alisertib and osimertinib in patients with metastatic EGFR-mutant non-small cell lung ca…
-
CLINICAL_TRIALS research · 2024-06-07Clinical Trial Update: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating whether adding immune checkpoint inhibitors to platinum-based chemotherapy improves outcomes in EGFR/ALK/R…
-
CLINICAL_TRIALS trial_result · 2024-06-06Clinical Trial Update: FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating FLT3 ligand immunotherapy in combination with stereotactic radiotherapy for advanced non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2024-06-06Clinical Trial Update: Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of Modified Si Jun Zi Tang in perioperative treatment for non-small cell lung canc…
-
CLINICAL_TRIALS research · 2024-06-05Clinical Trial Update: Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy [Phase 2]
A Phase 2 clinical trial from Fudan University is evaluating treatment response adapted hybrid radiotherapy as first-line therapy for metast…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) [Phase 2]
Phase 2 trial results for the combination of tepotinib and osimertinib in osimertinib-relapsed MET-amplified non-small cell lung cancer (INS…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Clinical trial update reports completion and posted results for ADXS-503 with or without pembrolizumab in metastatic non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases [Phase 2]
A Phase 2 clinical trial update evaluating the efficacy and resistance mechanisms of an investigational product (IP) in non-small cell lung …